Thermo Fisher Scientific Inc

TMOS34.SA ยท Healthcare ยท Diagnostics & Research ยท BRL ยท Fundamentals
Asset-light

Physical assets are 14.5% of total assets, a light footprint. Capex is 0.55x depreciation while free cash flow yield is positive, which can mean an aging base that is still throwing off cash. ROIC is 8.7%, above an 8% cost-of-capital hurdle.

Fixed-asset turnover is 4.22x. Compare it with other names in the same basket.

Physical asset ratio
14.5%
Net PP&E plus inventory, divided by total assets. Above 50% is a heavy footprint.
Fixed asset turnover
4.22x
Revenue per dollar of the physical asset base.
Capex / D&A
0.55x
Above 1.0x means the physical base is being replaced or expanded.
Tangible book / share
-BRL 31.37
Assets minus goodwill, intangibles, and liabilities, per share.
Price / tangible book
โ€”
Price BRL 72.87.
Fixed-charge coverage
7.03x
EBITDA minus capex, divided by interest plus short-term debt.
FCF yield
0.5%
Latest free cash flow divided by current market cap (BRL 1,293.29B).
ROIC
8.7%
After-tax operating income over equity plus debt minus cash. Operating income / net PP&E is 0.73x.

Footprint and return

Turnover and reinvestment

Year Physical FAT Capex/D&A TBV/sh Coverage FCF ROIC EBIT/PP&E
2018 12.8% 5.85x 0.33x -BRL 31.68 2.81x BRL 3.79B 7.7% 0.91x
2019 15.1% 4.69x 0.41x -BRL 25.21 4.51x BRL 4.05B 8.9% 0.81x
2020 15.5% 4.82x 0.63x -BRL 10.64 15.60x BRL 6.82B 15.9% 1.17x
2021 15.7% 3.98x 0.97x -BRL 157.13 3.09x BRL 7.02B 12.6% 1.04x
2022 17.0% 4.13x 0.66x -BRL 37.54 9.36x BRL 6.91B 10.9% 0.77x
2023 16.3% 3.89x 0.48x -BRL 35.82 6.88x BRL 6.55B 8.9% 0.62x
2024 16.2% 3.97x 0.45x -BRL 30.76 7.29x BRL 7.27B 8.8% 0.68x
2025 14.5% 4.22x 0.55x -BRL 31.37 7.03x BRL 6.29B 8.7% 0.73x
  • Principal due is short-term debt, the amount reported as due within a year.
Latest year inputs (2025)
Net PP&E: BRL 10.57B
Inventory: BRL 5.43B
Total assets: BRL 110.34B
Goodwill: BRL 49.36B
Intangibles: BRL 15.84B
Liabilities: BRL 56.93B
Tangible book: -BRL 11.79B
Shares: 375,708,060
Revenue: BRL 44.56B
Capex: BRL 1.53B
D&A: BRL 2.78B
EBITDA: BRL 11.51B
Interest: BRL 1.42B
Short-term debt: BRL 0.00
Free cash flow: BRL 6.29B
Operating income: BRL 7.75B
Invested capital: BRL 82.70B
Tax rate: 7.5%